Engagement in Legal Matters at PepGen Inc.
Investors are presented with a unique opportunity to take an active role in addressing potential securities fraud claims against PepGen Inc. This initiative is led by a dedicated national shareholder rights litigation firm.
Understanding the Class Action Lawsuit
The Schall Law Firm has issued a reminder to investors regarding a class action lawsuit against PepGen Inc. This lawsuit is based on allegations of violations under the Securities Exchange Act of 1934. Specifically, it relates to sections 10(b) and 20(a), as well as Rule 10b-5, which involves the misrepresentation of information concerning the company's drug candidate.
The Substance of the Allegations
The allegations suggest that PepGen's drug candidate, PGN-EDO51, did not meet safety and effectiveness standards that were communicated to investors. Reports indicate that the company's CONNECT2 study may have been insufficient for FDA approval and possibly posed risks to its participants. Such discrepancies have led to claims that PepGen's public statements were not only misleading but materially false during the class period.
Who is Affected?
Investors who purchased securities of PepGen from a specified period are particularly encouraged to connect with the Schall Law Firm. Anyone who may have experienced financial losses as a result of the company's actions should consider their legal options.
Getting Involved
If you are a shareholder facing losses, contacting the Schall Law Firm is a prudent next step. Their team can provide free consultations to discuss individual circumstances and outline potential avenues for recovery.
Potential Outcomes of the Lawsuit
The outcome of this class action could not only assist affected investors in recovering losses but also bring to light the regulations and standards that companies must adhere to regarding truthful disclosures. It is essential for investors to understand that the lawsuit can potentially provide a platform for accountability and greater transparency in company practices.
The Role of the Schall Law Firm
Specializing in securities class action lawsuits, the Schall Law Firm represents a broad spectrum of investors across various markets. With extensive experience in advocating for shareholder rights, their expertise is crucial in navigating the complexities of such legal matters. They strive to inform investors of their rights and assist in safeguarding those rights through legal channels.
Contact Information
Troubled investors can reach out to Brian Schall at the firm located at 2049 Century Park East, Suite 2460, for further discussion on their situation. The office phone number is 310-301-3335, and additional information can be found on their website. Communication is encouraged to pursue any claims related to the class action lawsuit.
Frequently Asked Questions
What is the purpose of the lawsuit?
The lawsuit aims to address allegations of securities fraud against PepGen Inc., related to misleading statements about their drug candidate.
Who qualifies to join the class action?
Investors who purchased PepGen securities during the specified class period and suffered losses may qualify to join.
When is the deadline to participate?
The cutoff date for investors to get involved in this action is set for August 8.
What should affected investors do?
Affected investors should reach out to the Schall Law Firm for guidance on how to proceed with their claims.
What is the significance of this lawsuit?
This lawsuit could help ensure that investors receive the accountability and transparency they deserve from PepGen Inc. regarding their public disclosures.
